Adult Leukemia Research Center

描述(申请人提供)：该计划项目的总体目标是改进异基因造血细胞移植(HCT)作为治疗血液系统恶性肿瘤的方法。具体地说，我们建议进行实验室和临床研究，以扩大移植的可用性，降低移植物抗宿主病的发生率和严重程度，并减少移植后恶性疾病复发的发生率。提出了四个单独的项目： 1.移植物抗宿主病的免疫遗传学 2.非清髓性异基因造血细胞移植。 3.髓系恶性肿瘤的特异性过继免疫治疗。 4.靶向T细胞反应性根除白血病。 此外，还要求在生物统计学、分子诊断、细胞处理、长期随访和管理方面提供核心支持。 我们成功开展拟议工作的能力大大得益于：(1)一大批研究人员都专注于HCT的一般主题；(2)我们中心支持这一主题的强大的临床前研究计划；以及(3)我们中心每年治疗500名移植患者。

DESCRIPTION (provided by applicant): The overall goal of this program project is to improve allogeneic hematopoietic cell transplantation (HCT) as treatment for hematological malignancies. Specifically we proposed laboratory and clinical studies to broaden the availability of transplantation, to decrease the incidence and severity of graft-versus-host disease, and to reduce the incidence of malignant disease recurrence post transplant. Four individual projects are proposed: 1. Immunogenetics of Graft-versus-host Disease. 2. Nonmyeloablative Hematopoietic Cell Allotransplants. 3. Specific Adoptive Immunotherapy of Myeloid Malignancy. 4. Targeting T Cell Reactivity for Leukemia Eradication. In addition, core support is requested in biostatistics, molecular diagnostics, cell processing, long-term follow-up, and administration. Our ability to successfully carry out the proposed work is greatly benefited by: (1) the existence of a large group of investigators all focused on the general topic of HCT; (2) strong preclinical research programs at our Center in support of this topic; and, (3) treatment of >500 transplant patients at our Center each year